logo

For the Inventor, By the Inventor

Cambridge, United Kingdom

Gw Research Limited


USPTO Granted Patents = 48



Trademarks = 30

Forward Citations = 1,176

Loading Chart...
Loading Chart...

50 inventors (with patents filed for the assignee):

goldMedal Geoffrey W Guy (32 out of 72 patents)

silverMedal Stephen Wright (27 out of 60 patents)

bronzeMedal Orrin Devinsky (16 out of 27 patents)

4.  Benjamin Whalley (9 out of 20 patents)

5.  Colin Stott (8 out of 17 patents)

6.  Marie Woolley-Roberts (7 out of 10 patents)

7.  Volker Knappertz (6 out of 11 patents)

8.  James Brodie (6 out of 6 patents)

9.  Jitinder Wilkhu (4 out of 5 patents)

10.  Royston Gray (4 out of 6 patents)

11.  Livio Luongo (4 out of 4 patents)

12.  Elizabeth Thiele (3 out of 3 patents)

13.  Rohini Rajyalaxmi Rana (3 out of 3 patents)

14.  Rafael Maldonado (3 out of 5 patents)

15.  Daniela Parolaro (3 out of 5 patents)


Core Competencies:
Cannabinoids
Cannabidiol
Cannabidivarin
Neurodegenerative Diseases
Epilepsy Treatment
Autism Spectrum Disorder
Pharmaceutical Formulations
Oral Cannabinoid Formulations
Combination Therapies
Ovarian Carcinoma
Skeletal Muscle Diseases
Neuroprotection

48 patents:

1. 12150927 - Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders (2024-11-26),
2. 11963937 - Use of cannabinoids in the treatment of epilepsy (2024-04-23),
3. 11944600 - Use of cannabinoids in the treatment of a neurodegenerative disease or disorder (2024-04-02),
4. 11865102 - Cannabidiol preparations and its uses (2024-01-09),
5. 11806319 - Pharmaceutical composition comprising a cannabinoid (2023-11-07),
6. 11793770 - 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy (2023-10-24),
7. 11766411 - Use of cannabinoids in the treatment of epilepsy (2023-09-26),
8. 11752111 - Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia (2023-09-12),
9. 11701330 - Use of cannabinoids in the treatment of epilepsy (2023-07-18),
10. 11684598 - Use of cannabinoids in the treatment of epilepsy (2023-06-27),
11. 11679087 - Use of cannabinoids in the treatment of Angelman syndrome (2023-06-20),
12. 11633369 - Use of cannabinoids in the treatment of epilepsy (2023-04-25),
13. 11590087 - Cannabidiol-type cannabinoid compound (2023-02-28),
14. 11446258 - Use of cannabinoids in the treatment of epilepsy (2022-09-20),
15. 11426362 - Oral cannabinoid formulations (2022-08-30),
GW Research Limited is a leading research and development company specializing in innovative solutions for various industries. With years of experience and a team of skilled scientists and engineers, we strive to deliver cutting-edge technologies and contribute to global advancements. Our areas of expertise include renewable energy, biotechnology, nanotechnology, and AI-driven solutions. Visit our website to learn more about our projects and collaborations.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

48 Patents

#21 in Cambridge

#359 in United Kingdom

#14,122 in the World

...
Cambridge, United Kingdom

Gw Research Limited

Forward Citations = 1,176

50 inventors:

goldMedal Geoffrey W Guy (32 out of 72 patents)

silverMedal Stephen Wright (27 out of 60 patents)

bronzeMedal Orrin Devinsky (16 out of 27 patents)

4.  Benjamin Whalley (9 out of 20 patents)

5.  Colin Stott (8 out of 17 patents)

Please report any incorrect information to support@idiyas.com
Loading…